Targeted inhibition of IL-6 signalling withtocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs 71st Annual Scientific Meeting of the American-College-of-Rheumatology/42nd Association-of-Rheumatology-Health-Professionals Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Genovese, M. WILEY-LISS. 2007: 4234–34

View details for Web of Science ID 000251781200051